Also found in: Wikipedia.
CMMLChronic Myelomonocytic Leukemia
CMMLContinuous Media Markup Language
CMMLChristian Missions in Many Lands, Inc. (est. 1921)
CMMLCivilian Manpower Management Letter
CMMLCoordinate Metrology and Measurement Laboratory (Ohio State University; Columbus, OH)
References in periodicals archive ?
Bone marrow samples were obtained from 10 patients with CMML (9 male patients; median age, 70 years; range, 53-83 years) between June 2010 and August 2011.
Fig 2: The key optimization benefits occur between level 2 and 4 of this model CMML Level Types of consolidation Benefits supported Level 2 A good understanding of Rack space reduction.
The first published description of CMML appeared in 1972, and the French-American-British group classified the condition as a subgroup of the myelodysplastic syndromes in 1982.
Greater than 75% of patients with CMML are over the age of 60 years.
Myelodysplastic/myeloproliferative neoplasms, most frequently chronic myelomonocytic leukemia (SM-CMML), are defined by myeloproliferative features (leukocytosis, specifically monocytosis in CMML, or thrombocytosis) and dysplastic features in 1 or more cell lines with or without an associated clonal cytogenetic abnormality.
To demonstrate the feasibility and power of this approach, we analyzed the very heterogeneous methylation pattern of the CpG islands of the tumor suppressor gene CDKN2B in bone marrow samples from patients with different MDS subtypes (RA, BARS, and RAEB) and from patients with CMML and AML, and in 32 control samples displaying only mild reactive changes.
Encouragingly, 31 percent of the patients with excess blast cells (22 of 71 RAEB patients, five of 11 RAEB-t patients and one of seven CMML patients) achieved a response.
An IND for a Phase I/II CMML monotherapy study of lenzilumab has been cleared by the Food and Drug Administration (NCT02546284).
The IND for KB003 in CMML, an orphan oncology indication, has been cleared by the FDA.
Seven months after the initial presentation, the patient died as a result of marrow replacement by CMML and overwhelming sepsis.
The IND for KB003 in CMML, an orphan oncology indication, has been cleared by the FDA, and KaloBios is currently undertaking site initiation activities for a Phase 1 study of KB003 in previously treated CMML patients.
As a result, KaloBios is initiating an open-label Phase I study designed to evaluate the safety, pharmacokinetics and clinical activity of KB003 in previously treated CMML patients.